Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy
In the modern DAA era, transplantation of HCV NAT+ donor hearts is not associated with increased risk of CAV or adverse clinical outcomes over intermediate-term follow-up.
Authors
- E. Adler
- Saima Aslam (ORCID: https://orcid.org/0000-0002-4051-5629)
- Kevin Paternostro
- Kimberly N. Hong (ORCID: https://orcid.org/0000-0003-3293-138X)
- Antoinette Birs (ORCID: https://orcid.org/0000-0001-7041-9075)
- N. Wettersten
Institutions
- UC San Diego Health System (US)
- University of California San Diego (US)
Publication Details
- Journal
- JHLT Open
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.jhlto.2025.100416
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00